Cargando…

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma

BACKGROUND: Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. METHODS: In this study, human osteosarcoma cell lines were prepar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yitian, Yu, Wei, Zhu, Jian, Wang, Junjie, Xia, Kaishun, Liang, Chengzhen, Tao, Huimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471997/ https://www.ncbi.nlm.nih.gov/pubmed/30995926 http://dx.doi.org/10.1186/s13046-019-1147-6

Ejemplares similares

Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2018)

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway
por: Feng, Shoumin, et al.
Publicado: (2018)

Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo
por: Zhu, Jian, et al.
Publicado: (2017)

A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep
por: Yu, Wei, et al.
Publicado: (2017)

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells
por: Dai, Qiang, et al.
Publicado: (2020)

A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing
por: Prapa, Malvina, et al.
Publicado: (2015)

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
por: Yu, Jiayi, et al.
Publicado: (2018)

Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma
por: Lin, Zili, et al.
Publicado: (2021)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
por: Halim, Leena, et al.
Publicado: (2022)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
por: Muliaditan, Tamara, et al.
Publicado: (2021)

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia
por: Wu, Lijuan, et al.
Publicado: (2023)

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
por: Mensali, Nadia, et al.
Publicado: (2023)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors
por: Long, Adrienne H., et al.
Publicado: (2015)

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
por: An, Na, et al.
Publicado: (2016)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
por: De Oliveira, Satiro N, et al.
Publicado: (2013)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

lncRNAs: function and mechanism in cartilage development, degeneration, and regeneration
por: Zhu, Jian, et al.
Publicado: (2019)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma
por: Murayama, Yudai, et al.
Publicado: (2021)

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
por: Chen, K H, et al.
Publicado: (2017)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells
por: Starr, Renate, et al.
Publicado: (2023)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells
por: Morita, Daisuke, et al.
Publicado: (2017)

Expression and Role of CD166 in the Chronic Kidney Disease
por: Sun, Yan, et al.
Publicado: (2015)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

Anti-CD19 chimeric antigen receptor T-cell followed by interferon−α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report
por: Ni, Jing, et al.
Publicado: (2022)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
por: Zhou, Hui, et al.
Publicado: (2018)

T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
por: Mihara, Keichiro, et al.
Publicado: (2017)

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
por: Xia, Yuan, et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

ANGI-03 Functional roles of CD166/activated leukocyte cell adhesion molecule (CD166/ALCAM) for glioblastoma invasion
por: Kijima, Noriyuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_icgjsq7cboc3otdot6sn82qd08